Rapport Therapeutics — Third Quarter 2026 Earnings Summary

Rapport Therapeutics reported a net loss of $40.2 million for the third quarter of 2026, driven by increased research and development expenses related to its clinical programs. The company achieved positive topline results from its Phase 2 trial of RAP-219 in adults with acute bipolar mania, meeting both primary and secondary endpoints with a statistically significant improvement in symptom scores. RAP-219 is currently being evaluated in two pivotal Phase 3 trials for focal onset seizures, with two additional Phase 3 trials for bipolar mania expected to initiate in the second half of 2027. Following a financing event in October 2026 that raised approximately $410.7 million, the company holds $815.4 million in cash and cash equivalents as of November 3, 2026, providing a runway through the end of 2029.